Scancell Share Discussion Threads

[jaknife] 04/12/2024 18:12

Proposed Placing and Subscription to raise a minimum of £8.5 million


^^ At 10.5p

[rogerbridge] 04/12/2024 17:50

There is no future for companies listed in the UK.
Has the time come to split the company and list part in the US?

[markingtime] 04/12/2024 16:37

I see that one of our number seems to have been claiming to have made "stacks of money" trading Bitcoin.Lets see how that goes, now that the Bitcoin plummet has started today, following the arrests of some of the Russian money-launderers who have been relying on stupid people to provide them with liquidity.

[markingtime] 04/12/2024 16:25

Big close coming, as the line of stock finally gets cleaned out?

[2tyke] 04/12/2024 16:14

I certainly wouldn't listen to the utterly clueless EE.

[nigelpm] 04/12/2024 16:13

Re: genmab I missed the last earlier barrage of posts because I dared to mention a logical outcome. Summed up nicely by EE earlier. If you are on the hook for somewhere between 400 and 1.2bn you might as well see if you can get away with an offer for the whole business. Take what you want and sell the rest.

[nigelpm] 04/12/2024 16:07

Fwiw, this is right back to bargain territory even though I don't necessarily see the heady heights of much above 50p, that is still at least 3x current price with some equity dilution thrown in for good measure.

[2tyke] 04/12/2024 16:07

Lol nigel ..what exactly is this 'market' that you refer to ?
It has no nervous system you know.
It's merely a collection of 'trades' from disparate individuals. They decide what to do based on what others are doing and how price has behaved in the past.
Notice the huge rejection of 15.3p today by the bears. They don't want to know about higher prices.

[nigelpm] 04/12/2024 15:53

Back to 13p. Market needs more convincing.

[2tyke] 04/12/2024 15:50

Got to mention today's chuckle again.....'inane knows about money'
😂 😂
A classic....if only he had a clue.

[2tyke] 04/12/2024 15:48

I'm afraid that's it....
One of us (me) makes stacks investing in the most lucrative asset possible.
The other (you) is up to his neck in a risky little dreamers stock.
One of us makes money (namely tyke)...the other doesn't (namely inane), and has to sit in a kiosk all day.
Did I mention it was going lower ? Even before the RNS was issued?
Are you still on the moon ? 😂

[ivyspivey] 04/12/2024 15:41

Nana as you say you don’t work in the industry.

Wish I had your wisdom when I was presented with our vision for 2035 including patient mapping and pipeline strategy last week,
I could have said ignore the 10 years in front of you and simply buy SCLP.If only it were that simple in the real world

[inanaco] 04/12/2024 15:09

yes of course you are .....

and yet you are here ... posting on a little Biotech

"2tyke" "a small child, especially a cheeky or mischievous one"

stop dreaming ...

[marcusl2] 04/12/2024 15:06

For ambitious junior life sciences companies, often the ultimate goal is securing partnerships with well-funded industry players to propel drug development toward commercial success.

For many smaller innovators, bringing a promising molecule from the lab through clinical trials and onto the market is a daunting challenge requiring significant time and financial resources.

For Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF), a UK-based specialist in immuno-oncology, this challenge has been met with two notable partnerships worth a potential $1.2 billion — both with Danish biotech company Genmab (CSE:GEN).


Genmab
The most recent deal grants Genmab exclusive global rights to develop and commercialise a monoclonal antibody from Scancell’s GlyMab platform.

Analysts estimate an upfront payment of around $5 million, alongside milestone payments tied to development, regulatory, and commercial achievements. Scancell will also earn royalties on net sales of products resulting from the collaboration.

The licensed antibody is one of five in Scancell’s portfolio targeting glycan structures associated with cancer. These partnerships underscore the potential of Scancell’s GlyMab platform, though the company’s ambitions extend well beyond these agreements.

SCIB1: Progress in advanced melanoma
Scancell has made significant strides in developing SCIB1, its lead asset targeting advanced melanoma, a form of skin cancer.

The SCOPE trial, testing SCIB1 in combination with checkpoint inhibitors ipilimumab and nivolumab, has yielded promising results in 25 patients.

At six months, 80% of participants experienced no disease progression, with 20% achieving complete remission. The overall disease control rate — including stable disease or tumour shrinkage — stood at 84%, and 72% of patients showed significant tumour reduction, improving over time.

These results compare favourably with outcomes from checkpoint inhibitors alone, which typically achieve 65% progression-free survival and a 16% complete remission rate. The data suggest SCIB1 enhances both the durability and effectiveness of treatment.

Dr Heather Shaw, an oncologist at University College Hospital in London, praised SCIB1 for its potential to improve first-line therapies for advanced melanoma patients while maintaining a strong safety profile.

Scancell’s chief scientist, Professor Lindy Durrant, highlighted progression-free survival as a key metric for future trials, stating: “The SCOPE study continues to yield excellent results with a PFS of 80% and five patients now achieving a complete response.”

Advantages of SCIB1
SCIB1 is the only off-the-shelf DNA cancer vaccine currently in development for melanoma. Unlike personalised cancer vaccines, which are tailored to individual patients, off-the-shelf vaccines are expected to be less expensive, easier to manufacture, and more readily available.

Analysts at Panmure Liberum have noted the potential advantages of this approach, predicting that it could make Scancell a leader in this emerging field. Easy of use is enhanced by a tie-up with PharmaJet, a specialist in needle-free injections.

Modi-1
In addition to SCIB1, Scancell is advancing Modi-1, another phase II asset targeting renal cell carcinoma (RCC) initially.

Data from the ModiFY study, which combines Modi-1 with checkpoint inhibitors for RCC, is anticipated in the first half of 2025.

New leadership
Last month, Scancell appointed Dr Phil L’Huillier as chief executive, succeeding Professor Durrant.

L’Huillier brings a wealth of experience, having previously led CatalYm, where he advanced products from phase I to phase IIb and raised over $200 million.

He has also been involved in the development of multiple biotech companies, including Achilles Therapeutics and Blink Therapeutics.

Panmure Liberum welcomed his appointment, stating: “We expect the appointment to add company development experience to the solid scientific foundations of Scancell and should enable the maturation of the company as it reaches the next stage.”

What's it all worth?
Panmure Liberum rates Scancell shares as a ‘buy,’ with a price target of 23.3p — a 65% premium to the current price. The firm believes positive clinical data could trigger a re-rating of the stock, particularly as awareness grows around the potential of cancer vaccines.

“The growing awareness of the potential in the cancer vaccine field is translating to a rise in the profile of Scancell,” Panmure noted.

With two major partnerships, a strong pipeline, and a new CEO poised to drive its next phase of growth, Scancell is positioning itself as a key player in the competitive and evolving field of cancer immunotherapy.

[2tyke] 04/12/2024 15:03

Inane,
I'm a big investor in the most lucrative asset humans have EVER known.
I don't piddle about with a very very tiny little biotech that I'm up to my poor little neck in and constantly average down.
Please don't talk about money !

[inanaco] 04/12/2024 15:02

well the issue is nobody is questioning the posts on the LSE from a technical point

[bermudashorts] 04/12/2024 15:00

inanaco,

I'm not suggesting for one second that they're exiting early - they've already been invested for over 4 years, not a flip trade by anyone's standards. I was simply commenting on the reaction to Nigel's comment re. a potential offer from Genmab.

By the way, I agree with you on the avidimab point.

[marcusl2] 04/12/2024 15:00

The Glymab platform generates antibodies that target sugar motifs rather than proteins, which the company reckons offer differentiated properties, particularly as potential treatments for cancer as aberrant expression of glycans is often encountered on the surface of malignant cells.



Genmab may now need to pull out the big bucks....

[inanaco] 04/12/2024 15:00

would you like to comment on this total nonsense Bermuda ...

"""Pharmas spend up to 10-15 years determining and refining their strategic focus constantly and have a clear vision and pathway at least 10 years ahead.They do not change that and make major strategic decisions like deciding to buy the likes of SCLP based on however great the potential is of it does not fit in with their plan."""

[inanaco] 04/12/2024 14:47

your link Bermuda further emphasizes that KONAR A post is wrong

"pre"

And for anyone saying upfront cash like that isn't possible - Genmab paid USD1.8 Billion for ProfoundBio which came with 3 pre-clinical antibodies (i.e. 600 Million each, paid up front in cash)

[inanaco] 04/12/2024 14:44

you can put this straight back on you Bermuda .... Do you have evidence that they will exit very early, only they seem to be extending and developing the partnership further

any fool can make a prediction ...look at Ivy's inputs

but you have no idea like the rest of us what there intention is ...

lets call that "blind speculation"


Bermudashorts4 Dec '24 - 14:38 - 15030 of 15031
0 0 0
TF

Genuine question, if you don't agree that it's not easy for Redmile to exit from such a large position, how do you see Redmile achieving their exit?

I'm very happy to agree to disagree, but not sure I'd use the term 'daft' to describe any hedge fund manager walking away with a 300% return from an investment in an early stage biotech.

[bermudashorts] 04/12/2024 14:38

TF

Genuine question, if you don't agree that it's not easy for Redmile to exit from such a large position, how do you see Redmile achieving their exit?

I'm very happy to agree to disagree, but not sure I'd use the term 'daft' to describe any hedge fund manager walking away with a 300% return from an investment in an early stage biotech.